Phosphoserine aminotransferase 1 (PSAT1) may be an oncogene that plays an important role in various cancer types. However, there are still many gaps in the expression of PSAT1 gene and its biological impact in different types of tumors. Here, we performed an integrated pan-cancer analysis to explore the potential molecular mechanisms of PSAT1 in cancers. We found that most human tumors express higher levels of PSAT1 than normal tissues, and that higher PSAT1 expression is associated with worse prognosis in Lung adenocarcinoma (LUAD), Pan-kidney cohort (KIPAN) and breast invasive carcinoma (BRCA), etc. In BRCA cases, the prognosis of patients with altered PSAT1 was worse than that of patients without alteration. In addition, PSAT1 hypermethylation is associated with T cell dysfunction and shortened survival time in BRCA. The Gene Set Enrichment Analysis (GSEA) analysis showed that PSAT1 can be enriched into the classic signaling pathways of cancer such as mTORC1 signaling, MYC targets and JAK STAT3. Further analysis demonstrated that PSAT1 was enriched in immune related signaling pathways in LUAD and BRCA. The results of immunoassay showed that PSAT1 was associated with immune cell infiltration in multiple cancer species. Furthermore, expression of PSAT1 was correlated with both tumor mutational burden (TMB) and microsatellite instability (MSI) in BRCA. Additionally, a remarkable correlation was found between PSAT1 expression and TMB in LUAD, and the expression of PSAT1 was negatively correlated with the Tumor Immune Dysfunction and Exclusion (TIDE) value, suggesting a good effect of immunotherapy. Together, these data suggest that PSAT1 expression is associated with the clinical prognosis, DNA methylation, gene mutations, and immune cell infiltration, contributing to clarify the role of PSAT1 in tumorigenesis from a variety of perspectives. What's more, PSAT1 may be a new biomarker for survival and predicting the efficacy of immunotherapy for LUAD and BRCA.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9465327 | PMC |
| http://dx.doi.org/10.3389/fgene.2022.975381 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
FOXC1-mediated serine metabolism reprogramming enhances colorectal cancer growth and 5-FU resistance under serine restriction.
Cell Commun Signal
January 2025
Endoscopy Center, Department of Gastroenterology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Colorectal cancer (CRC) is the most common gastrointestinal malignancy, and 5-Fluorouracil (5-FU) is the principal chemotherapeutic drug used for its treatment. However, 5-FU resistance remains a significant challenge. Under stress conditions, tumor metabolic reprogramming influences 5-FU resistance.
View Article and Find Full Text PDFPSAT1 promotes the progression of colorectal cancer by regulating Hippo-YAP/TAZ-ID1 axis via AMOT.
Mol Cell Biochem
December 2024
Department of Pathology, Nanfang Hospital, School of Basic Medical Sciences, Southern Medical University, Guangzhou, 510515, Guangdong, China.
Colorectal cancer (CRC) ranks third for morbidity and second for mortality among all digestive malignant tumors worldwide, but its pathogenesis remains not entirely clear. Bioinformatic analyses were performed to find out important biomarkers for CRC. For validation, reverse transcription-quantitative PCR, western blotting, and immunohistochemistry were performed.
View Article and Find Full Text PDFAdipoRon mitigates liver fibrosis by suppressing serine/glycine biosynthesis through ATF4-dependent glutaminolysis.
Ecotoxicol Environ Saf
December 2024
Department of Gastroenterology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China. Electronic address:
AdipoRon has been validated for its ability to reverse liver fibrosis, yet the underlying mechanisms remain to be thoroughly investigated. Collagen, predominantly synthesized and secreted in hepatic stellate cells (HSCs), relies on glycine as a crucial constituent. Activating transcription factor 4 (ATF4) serves as a pivotal transcriptional regulator in amino acid metabolism.
View Article and Find Full Text PDFFetal Phenotyping and Whole Exome Sequencing for 12 Egyptian Families With Serine Biosynthesis Defect: Novel Clinical and Allelic Findings With a Founder Effect.
Prenat Diagn
December 2024
Human Genetics Department, Medical Research Institute, Alexandria University, Alexandria, Egypt.
Article Synopsis
- The study aimed to better understand severe serine biosynthesis defects by examining prenatal and postnatal effects in 12 unrelated Egyptian families with suspected Neu-Laxova syndrome (NLS).
- Researchers employed fetal ultrasound, postnatal assessments, and whole exome sequencing (WES) to analyze this new cohort and reviewed existing literature for a broader context.
- Findings included novel clinical signs and the identification of several genetic variants, expanding the understanding of serine biosynthesis disorders and highlighting the importance of prenatal exome sequencing.
Identification and Validation of Serum Biomarkers to Improve Colorectal Cancer Diagnosis.
Cancer Med
December 2024
Department of Pathology, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Article Synopsis
- The study addresses the urgent need for reliable biomarkers in colorectal cancer (CRC) diagnosis, highlighting limitations in current methods and the potential for novel, non-invasive solutions.
- Using advanced genomic and proteomic technologies, researchers identified five promising biomarkers: INHBA, MMP7, PSAT1, SLC7A5, and TGFBI, which showed significantly higher expression levels in CRC patients compared to healthy controls.
- The biomarkers demonstrated strong diagnostic accuracy, with AUC values between 0.8361 and 0.9869, suggesting they could greatly improve early detection and precision in CRC diagnostic practices.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!